Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 20, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced that on December 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 720,400 shares of its common stock and 276,200 restricted stock units ("RSUs") to thirty-seven (37) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
圣地亚哥，2024年12月20日 /美通社/ -- Avidity Biosciences, Inc.（纳斯达克：RNA），一家致力于提供新的RNA治疗类药物——抗体寡核苷酸结合物（AOCs）的生物制药公司，今天宣布在2024年12月20日，Avidity董事会的人力资本管理委员会向三十七名（37）名新的非执行员工授予了非合格股票期权奖励，以购买其普通股的总计720,400股以及276,200个限制性股票单位（“RSUs”），根据Avidity Biosciences, Inc. 2022年雇佣诱因激励奖励计划（“2022诱因计划”）。这些奖励是作为诱因，旨在促使员工根据纳斯达克上市规则5635(c)(4)与Avidity签订雇佣合同。
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Avidity, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Avidity, pursuant to Nasdaq Listing Rule 5635(c)(4).
2022诱因计划专门用于向未曾是Avidity员工的个体，或在经历真实的非雇佣期间后，授予股票奖励，以促使这些个体与Avidity签订雇佣合同，依据纳斯达克上市规则5635(c)(4)。
The options have an exercise price of $31.82 per share, which is equal to the closing price of Avidity's common stock on The Nasdaq Global Market on December 20, 2024, or the vesting commencement date. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee's continued employment with Avidity on such vesting dates. The RSUs will vest in four equal installments on the first four anniversaries of the vesting commencement date, subject to each employee's continued employment with Avidity on such vesting dates. The awards are subject to the terms and conditions of the 2022 Inducement Plan and the terms and conditions of a stock option agreement or RSU agreement, as applicable, covering the grant.
这些期权的行使价格为每股31.82美元，该价格等于Avidity普通股在2024年12月20日的纳斯达克全球市场收盘价或归属开始日期。受股票期权限制的股份将在四年内解锁，25%的股份将在归属开始日期的一年周年时解锁，其余股份将在随后36个月内按月均匀解锁，前提是每位员工在这些解锁日期继续在Avidity工作。这些RSUs将在归属开始日期的前四个周年日平均解锁，前提是每位员工在这些解锁日期继续在Avidity工作。所有奖励均需遵从2022诱因计划的条款和条件及适用的股票期权协议或RSU协议的条款和条件。
About Avidity
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit and engage with us on LinkedIn and X.
关于Avidity
Avidity Biosciences, Inc. 的使命是通过提供一种新型RNA疗法——抗体寡核苷酸 conjugates (AOCs)，来深刻改善人们的生活。Avidity正在用其专有的AOCs革命性地改变RNA领域，这些AOCs旨在结合单克隆抗体的特异性与寡核苷酸疗法的精准度，以针对以前无法用现有RNA疗法处理的靶向和疾病。利用其专有的AOC平台，Avidity展示了首次成功将RNA靶向递送到肌肉，并在三种罕见神经肌肉疾病的临床开发项目中处于领先地位：肌强直性营养不良症 type 1 (DM1)、杜氏肌营养不良症 (DMD) 和面肩肱肌营养不良症 (FSHD)。Avidity还在推进两个完全拥有的精准心脏病学开发候选者，旨在应对罕见的遗传性心肌病。此外，Avidity正在通过与关键合作伙伴的合作，扩大AOCs的影响力，推进和扩展其管线，包括心脏病学和免疫学领域的项目。Avidity总部位于加州圣地亚哥。有关我们的AOC平台、临床开发管线和人员的更多信息，请访问并在LinkedIn和X上与我们互动。
Investor Contact:
Kat Lange
(619) 837-5014
[email protected]
投资者联系人：
Kat Lange
(619) 837-5014
[email protected]
Media Contact:
Di Andrews
(619) 837-5016
[email protected]
媒体联系人：
Di Andrews
(619) 837-5016
[email protected]
SOURCE Avidity Biosciences, Inc.
来源 Avidity Biosciences, Inc.